Resurrecting an old drug - A flash in the pan or here to stay?

International Journal of Clinical Practice

Volumn 63, Issue 1, 2009, Pages 3-6

  Viljoen, A ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; COLESTIPOL; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MK 0542; NICOTINAMIDE; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CELL ENERGY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; ENERGY METABOLISM; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; FOLLOW UP; HAIRY TONGUE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MITOCHONDRION; MORTALITY; NICOTINIC ACID DEFICIENCY; NONHUMAN; PELLAGRA; PRIORITY JOURNAL; RESPIRATORY CHAIN; SIDE EFFECT; SUSTAINED DRUG RELEASE;

HUMANS; LEGISLATION, DRUG; NIACINAMIDE;

EID: 57649245633     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01967.x     Document Type: Editorial

References (38)

1. + and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008 324 : 883 93.
2. Berg JM, Tymoczko JL, Stryer L. Biochemistry, 5th edn. New York : W.H. Freeman and Company, 2002.
3. Hegyi J, Schwartz R, Hegyi V. Pellagra: dermatitis, dementia, and diarrhoea. Int J Dermatol 2004 43 : 1 5.
4. Koehn CJ, Elvehjem CA. Further studies on the concentration of the antipellagra factor. J Bio Chem 1937 118 : 693 9.
5. Altschul R, Herman IH. Influence of oxygen inhalation on cholesterol metabolism. Arch Biochem Biophys 1954 51 : 308 9.
6. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955 54 : 558 9.
7. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy and safety. Curr Opin Lipidol 2007 18 : 415 20.
8. 3H-labelled nicotinic acid studied by autoradiography. Life Sci 1964 3 : 867 71.
9. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003 278 : 9869 74.
10. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005 115 : 3400 3.
11. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008 101 : 20B 6B.
12. Parsons WB, Achor RW, Berge KG, McKenzie BF, Barker NW. Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc Staff Meet Mayo Clin 1956 31 : 377 90.
13. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975 231 : 360 81.
14. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 8 : 1245 55.
15. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987 257 : 3233 40.
16. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988 223 : 405 18.
17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 7.
18. Baigent C, Keech A, Kearney PM et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
19. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002 360 : 7 22.
20. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005 46 : 1225 8.
21. Wierzbicki AS. Intervening on HDL-C: is it possible? Does it work? Int J Clin Pract 2007 61 : 1782 6.
22. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004 58 : 706 13.
23. Alsheikh-Ali AA, Karas RH. The safety of Niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol 2008 101 (Suppl. 9B 13B.
24. Kamal-Bahl S, Burke T, Watson D, Wentworth C, Ma L. Dosage and titration patterns of extended release niacin in clinical practice. Circulation 2006 113 : E814. American Heart Association 7th Scientific Forum of Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC, 2006.
25. Auliffe M, Piechuta H, Nicoll-Griffith DA et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007 50 : 794 806.
26. Maccubbin D, Bays HE, Olsson AG et al. Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidaemia. Int J Clin Pract 2008 62 : 1959 70.
27. Kamal-Bahl S, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007 99 : 530 4.
28. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002 162 : 1568 76.
29. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005 95 : 254 7.
30. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008 31 : S12 54.
31. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998 21 : 179 82.
32. National Institute for Health and Clinical Excellence. Diabetes - Type 2 (Update) (Online). http://www.nice.org.uk/Guidance/CG66 (accessed October 2008).
33. Hughes S. Experts Speculate on Cordaptive Rejection (Online). http://www.theheart.org/article/860399.do (accessed October 2008).
34. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 2008 62 : 981 7.
35. Deyo RA. Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice. J Am Board Fam Pract 2004 17 : 142 9.
36. National Heart Lung and Blood Institute. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. ClinicalTrials.gov (Online). http://clinicaltrials.gov/ct2/show/NCT00461630 (accessed October 2008).
37. National Heart Lung and Blood Institute. Niacin Plus Statin to Prevent Vascular Events: AIM-HIGH. ClinicalTrials.gov (Online). http://www. clinicaltrials.gov/ct/show/NCT00120289 (accessed October 2008).
38. An audience with Clifford Rosen. Nat Rev Drug Discov 2008 7 : 382.